IRadimed vs Xtant Medical
IRMD and XTNT side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How IRMD and XTNT compare
IRadimed is the larger company, worth 29 times as much as Xtant Medical ($1.1B against $37.9M).
IRadimed grew revenue faster over the last twelve months (11.0% versus −14.3% for Xtant Medical).
IRadimed keeps more of each dollar of sales as profit, with a net margin of 26.8% compared with −10.2% at Xtant Medical.
IRadimed pays a dividend yielding 0.89%; Xtant Medical does not pay one.
IRadimed scores higher on the StockData Score (18 against 9 for Xtant Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | IRMD | XTNT |
|---|---|---|
| Size and price | ||
| Market cap | $1.1B | $37.9M |
| Share price | $86.58 | $0.270 |
| Change, 1 year | 0.59% | −64.1% |
| Change, 5 years | 122% | −69.7% |
| Beta (5Y) | 0.76 | 0.60 |
| Employees | 166 | 151 |
| StockData Score | ||
| Total score | 18 (better) | 9 |
| Valuation score | 0 | 3 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 6 (better) | 2 |
| Health score | 6 (better) | 3 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 46.3× | – |
| P/S | 12.4× | 0.3× (better) |
| P/B | 10.4× | 0.9× (better) |
| EV/EBITDA | 34.2× | – |
| P/FCF | 42.4× | – |
| PEG | 2.35 | – |
| FCF yield | 2.4% (better) | −1.8% |
| Fair value | $54.01 | $1.08 |
| Margin of safety | −60.3% | 74.9% (better) |
| Growth | ||
| Revenue growth (TTM) | 11.0% (better) | −14.3% |
| Revenue growth, 5Y average | 21.5% (better) | 20.2% |
| Net income growth (TTM) | 13.2% | – |
| EPS growth (TTM) | 13.3% | – |
| EPS growth, 5Y average | 73.9% | – |
| Profitability | ||
| Gross margin | 75.5% (better) | 59.4% |
| Operating margin | 32.3% (better) | −9.6% |
| Net margin | 26.8% (better) | −10.2% |
| FCF margin | 29.3% (better) | −0.64% |
| Return on equity | 23.4% (better) | −25.2% |
| Return on invested capital | 52.3% (better) | −15.8% |
| Financial health | ||
| Debt / equity | 0.00 | 0.28 (better) |
| Interest coverage | – | −3.8× |
| Current ratio | 8.99 (better) | 2.16 |
| Altman Z-score | 48.65 (better) | −2.65 |
| Piotroski F-score | 6 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.89% | – |
| Payout ratio | 67.6% | – |
| Shareholder yield | 0.89% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 61.4% | 106% |
| Held by insiders | 35.5% | – |
| Insider net buying, 12 months | −$16.0M | – |
| Short interest, % of float | 7.2% | – |
Go deeper
- IRMD stock overview
- IRMD income statement
- IRMD valuation and score
- XTNT stock overview
- XTNT income statement
- XTNT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.